Posters

Jetrea: Does it work?

Poster Details

First Author: M.Siddique UK

Co Author(s):    I. Khan   M. Musadiq                          

Abstract Details



Purpose:

To evaluate the efficacy and side effects of intravitreal ocriplasmin

Setting:

Hospital Based, Interventional study

Methods:

Suitable patients were identified for intravitreal Jetrea. Patients with VMT and stage 2 macular holes were included. ERM was an exclusion. OCT was performed on the day of injection to see if they still need injection or not.

Results:

We identified 12 patients out of which 2 settled without injection. Ten patients needed injection and 60 percent got VMT released in 28 days. No side effects were noted.

Conclusions:

Ocriplasmin is a good treatment for VMT and stage 2 macular holes.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy